Neomycin and plasma lipoproteins in type II hyperlipoproteinemia

Jeffrey M. Hoeg; Ernst J. Schaefer; Carol A. Romano; Ernestina Bou; Anita M. Pikus; Loren A. Zech; Kent R. Bailey; Richard E. Gregg; Peter W.F. Wilson; Dennis L. Sprecher; Alison M. Grimes; Nancy G. Sebring; Elaine J. Ayres; Claus E. Jahn; H. B. Brewer

doi:10.1038/clpt.1984.219

Neomycin and plasma lipoproteins in type II hyperlipoproteinemia

Jeffrey M. Hoeg, Ernst J. Schaefer, Carol A. Romano, Ernestina Bou, Anita M. Pikus, Loren A. Zech, Kent R. Bailey, Richard E. Gregg, Peter W.F. Wilson, Dennis L. Sprecher, Alison M. Grimes, Nancy G. Sebring, Elaine J. Ayres, Claus E. Jahn, H. B. Brewer

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9-mo, double-blind, randomized, crossover, placebo-controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safey, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%) decline in plasma cholesterol concentration was observed with neomycin. Most of this effect resulted from a 41 mg% (16%) decrease in low-density lipoprotein cholesterol concentration. No significant or consistent effect on the concentration of high-density lipoprotein cholesterol was observed. Monthly audiologic and renal evaluation disclosed no oto- or nephrotoxicity. Neomycin treatment in patients with type 11 hype rlipoproteinemia is an inexpensive and effective means of lowering the concentration of low-density lipoproteins and is free of significant side effects over a 3-mo period.

Original language	English (US)
Pages (from-to)	555-565
Number of pages	11
Journal	Clinical pharmacology and therapeutics
Volume	36
Issue number	4
DOIs	https://doi.org/10.1038/clpt.1984.219
State	Published - Oct 1984

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1038/clpt.1984.219

Cite this

Hoeg, J. M., Schaefer, E. J., Romano, C. A., Bou, E., Pikus, A. M., Zech, L. A., Bailey, K. R., Gregg, R. E., Wilson, P. W. F., Sprecher, D. L., Grimes, A. M., Sebring, N. G., Ayres, E. J., Jahn, C. E., & Brewer, H. B. (1984). Neomycin and plasma lipoproteins in type II hyperlipoproteinemia. Clinical pharmacology and therapeutics, 36(4), 555-565. https://doi.org/10.1038/clpt.1984.219

@article{0191e4f4aa124eb18e5afc37a75af3c5,

title = "Neomycin and plasma lipoproteins in type II hyperlipoproteinemia",

abstract = "Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9-mo, double-blind, randomized, crossover, placebo-controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safey, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%) decline in plasma cholesterol concentration was observed with neomycin. Most of this effect resulted from a 41 mg% (16%) decrease in low-density lipoprotein cholesterol concentration. No significant or consistent effect on the concentration of high-density lipoprotein cholesterol was observed. Monthly audiologic and renal evaluation disclosed no oto- or nephrotoxicity. Neomycin treatment in patients with type 11 hype rlipoproteinemia is an inexpensive and effective means of lowering the concentration of low-density lipoproteins and is free of significant side effects over a 3-mo period.",

author = "Hoeg, {Jeffrey M.} and Schaefer, {Ernst J.} and Romano, {Carol A.} and Ernestina Bou and Pikus, {Anita M.} and Zech, {Loren A.} and Bailey, {Kent R.} and Gregg, {Richard E.} and Wilson, {Peter W.F.} and Sprecher, {Dennis L.} and Grimes, {Alison M.} and Sebring, {Nancy G.} and Ayres, {Elaine J.} and Jahn, {Claus E.} and Brewer, {H. B.}",

year = "1984",

month = oct,

doi = "10.1038/clpt.1984.219",

language = "English (US)",

volume = "36",

pages = "555--565",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Neomycin and plasma lipoproteins in type II hyperlipoproteinemia

AU - Hoeg, Jeffrey M.

AU - Schaefer, Ernst J.

AU - Romano, Carol A.

AU - Bou, Ernestina

AU - Pikus, Anita M.

AU - Zech, Loren A.

AU - Bailey, Kent R.

AU - Gregg, Richard E.

AU - Wilson, Peter W.F.

AU - Sprecher, Dennis L.

AU - Grimes, Alison M.

AU - Sebring, Nancy G.

AU - Ayres, Elaine J.

AU - Jahn, Claus E.

AU - Brewer, H. B.

PY - 1984/10

Y1 - 1984/10

N2 - Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9-mo, double-blind, randomized, crossover, placebo-controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safey, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%) decline in plasma cholesterol concentration was observed with neomycin. Most of this effect resulted from a 41 mg% (16%) decrease in low-density lipoprotein cholesterol concentration. No significant or consistent effect on the concentration of high-density lipoprotein cholesterol was observed. Monthly audiologic and renal evaluation disclosed no oto- or nephrotoxicity. Neomycin treatment in patients with type 11 hype rlipoproteinemia is an inexpensive and effective means of lowering the concentration of low-density lipoproteins and is free of significant side effects over a 3-mo period.

AB - Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9-mo, double-blind, randomized, crossover, placebo-controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safey, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%) decline in plasma cholesterol concentration was observed with neomycin. Most of this effect resulted from a 41 mg% (16%) decrease in low-density lipoprotein cholesterol concentration. No significant or consistent effect on the concentration of high-density lipoprotein cholesterol was observed. Monthly audiologic and renal evaluation disclosed no oto- or nephrotoxicity. Neomycin treatment in patients with type 11 hype rlipoproteinemia is an inexpensive and effective means of lowering the concentration of low-density lipoproteins and is free of significant side effects over a 3-mo period.

UR - http://www.scopus.com/inward/record.url?scp=0021683660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021683660&partnerID=8YFLogxK

U2 - 10.1038/clpt.1984.219

DO - 10.1038/clpt.1984.219

M3 - Article

C2 - 6383687

AN - SCOPUS:0021683660

SN - 0009-9236

VL - 36

SP - 555

EP - 565

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 4

ER -

Neomycin and plasma lipoproteins in type II hyperlipoproteinemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this